Qian Wen-Jing, Yan Jin-Shan, Gang Xiao-Yu, Xu Lu, Shi Sha, Li Xin, Na Fang-Jian, Cai Lu-Tong, Li He-Ming, Zhao Ming-Fang
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189187. doi: 10.1016/j.bbcan.2024.189187. Epub 2024 Sep 22.
Intercellular adhesion molecule-1 (ICAM-1) is a versatile molecule that plays a critical role in various physiological and pathological processes, particularly in tumor development where its impact is bidirectional. On the one hand, it augments the immune response by promoting immune cell migration, infiltration, and the formation of immunological synapses, thus facilitating potent antitumor effects. Simultaneously, it contributes to tumor immune evasion and influences metastasis by mediating transendothelial migration (TEM), epithelial-to-mesenchymal transition (EMT), and epigenetic modification of tumor cells. Despite its significant potential, the full clinical utility of ICAM-1 has yet to be fully realized. In this review, we thoroughly examine recent advancements in understanding the role of ICAM-1 in tumor development, its relevance in predicting therapeutic efficacy and prognosis, as well as the progress in clinical translational research on anti-ICAM-1-based therapies, encompassing including monoclonal antibodies, immunotherapy, antibody-drug conjugate (ADC), and conventional treatments. By shedding light on these innovative strategies, we aim to underscore ICAM-1's significance as a valuable and multifaceted target for cancer treatment, igniting enthusiasm for further research and facilitating translation into clinical applications.
细胞间黏附分子-1(ICAM-1)是一种多功能分子,在各种生理和病理过程中发挥关键作用,尤其是在肿瘤发展过程中,其影响具有双向性。一方面,它通过促进免疫细胞迁移、浸润以及免疫突触的形成来增强免疫反应,从而促进强大的抗肿瘤作用。同时,它通过介导肿瘤细胞的跨内皮迁移(TEM)、上皮-间质转化(EMT)和表观遗传修饰,促进肿瘤免疫逃逸并影响转移。尽管ICAM-1具有巨大潜力,但其全部临床应用价值尚未完全实现。在本综述中,我们全面审视了在理解ICAM-1在肿瘤发展中的作用、其在预测治疗效果和预后方面的相关性以及基于抗ICAM-1疗法的临床转化研究进展,包括单克隆抗体、免疫疗法、抗体药物偶联物(ADC)和传统治疗方法。通过阐明这些创新策略,我们旨在强调ICAM-1作为癌症治疗中一个有价值且多方面的靶点的重要性,激发进一步研究的热情并促进其转化为临床应用。